|
57 Products |
| 57 Products |
|
190 Diseases |  |
11246 News |  |
| «12...9899100101102103104105106107108109110» |
- | Mayzent (siponimod) / Novartis
Enrollment change, Trial primary completion date: Efficacy and Tolerability of BAF312 in Patients With Polymyositis (clinicaltrials.gov) - Oct 22, 2015
P2, N=45, Recruiting, Sponsor: Novartis Pharmaceuticals
N=30 --> 45 | Trial primary completion date: Jan 2016 --> Dec 2016
- |||||||||| Zeposia (ozanimod) / BMS
New P3 trial: DAYBREAK: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis (clinicaltrials.gov) - Oct 22, 2015
P3, N=2350, Active, not recruiting, Sponsor: Receptos, Inc.
- |||| Enrollment open: Fingolimod Effect on Cytokine and Chemokine Levels (clinicaltrials.gov) - Oct 22, 2015
P4, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
N=30 --> 45 | Trial primary completion date: Jan 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- ||||| Zeposia (ozanimod) / BMS
Enrollment closed: SUNBEAM: Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) (clinicaltrials.gov) - Oct 16, 2015
P3, N=1200, Active, not recruiting, Sponsor: Receptos, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Trial completion, Trial primary completion date: Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms (clinicaltrials.gov) - Oct 15, 2015
P4, N=150, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Sep 2015
- || Trial primary completion date: STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) (clinicaltrials.gov) - Oct 7, 2015
P4, N=7000, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Sep 2015 Trial primary completion date: Dec 2015 --> Jul 2016
- Trial completion: Gilenya in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Sep 24, 2015
P2a, N=30, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2015 --> Jul 2016 Active, not recruiting --> Completed
- | Ponvory (ponesimod) / Juvise Pharma, Vanda
Enrollment open, Trial initiation date: Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD (clinicaltrials.gov) - Sep 24, 2015
P2, N=30, Recruiting, Sponsor: Actelion
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jun 2015 --> Sep 2015
- |||| iSONEP (sonepcizumab) / Pfizer, Apollo Endosurgery
Trial completion, Monotherapy: Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD (clinicaltrials.gov) - Sep 17, 2015
P2, N=158, Completed, Sponsor: Lpath, Inc.
Not yet recruiting --> Recruiting | Initiation date: Jun 2015 --> Sep 2015 Active, not recruiting --> Completed
- |||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment open: Extension Study of MT-1303 in Subjects With Crohn's Disease (clinicaltrials.gov) - Sep 17, 2015
P2, N=80, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Mayzent (siponimod) / Novartis
Enrollment change: Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Sep 9, 2015
P3, N=48, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting N=75 --> 48
- ||||| Velsipity (etrasimod) / Pfizer
New P2 trial: Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Aug 31, 2015
P2, N=180, Not yet recruiting, Sponsor: Arena Pharmaceuticals
- |||| Trial completion: PREFERMS: Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. (clinicaltrials.gov) - Aug 24, 2015
P4, N=881, Completed, Sponsor: Novartis Pharmaceuticals
N=75 --> 48 Active, not recruiting --> Completed
- |||||||||| Zeposia (ozanimod) / BMS
New P3 trial: An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Aug 24, 2015
P3, N=1200, Not yet recruiting, Sponsor: Receptos, Inc.
- ||||| Zeposia (ozanimod) / BMS
Biomarker, New P2 trial: Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Aug 24, 2015
P2, N=60, Not yet recruiting, Sponsor: Receptos, Inc.
- |||| Mayzent (siponimod) / Novartis
Trial primary completion date: Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) (clinicaltrials.gov) - Aug 19, 2015
P3, N=1530, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Nov 2016 --> Aug 2016
- mocravimod (KRP-203) / Priothera
Trial primary completion date: A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies (clinicaltrials.gov) - Aug 13, 2015
P1, N=10, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2016 --> Aug 2016 Trial primary completion date: Oct 2016 --> Mar 2017
- fingolimod / Generic mfg.
Trial primary completion date: MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) (clinicaltrials.gov) - Aug 13, 2015
P2/3, N=88, Recruiting, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Oct 2016 --> Mar 2017 Trial primary completion date: Jan 2016 --> Apr 2017
- cenerimod (ACT-334441) / Idorsia
Trial suspension: Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 (clinicaltrials.gov) - Aug 13, 2015
P1, N=32, Suspended, Sponsor: Actelion
Trial primary completion date: Jan 2016 --> Apr 2017 Recruiting --> Suspended
- Trial completion: ANSG: Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS (clinicaltrials.gov) - Aug 11, 2015
P4, N=30, Completed, Sponsor: Jochen Vehoff
Recruiting --> Suspended Recruiting --> Completed
- |||| Velsipity (etrasimod) / Pfizer
Enrollment open: OASIS: Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis (clinicaltrials.gov) - Jul 31, 2015
P2, N=240, Recruiting, Sponsor: Arena Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change, Trial termination: BiobankII: Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jul 22, 2015
P4, N=8, Terminated, Sponsor: Heinrich-Heine University, Duesseldorf
Not yet recruiting --> Recruiting N=250 --> 8 | Recruiting --> Terminated; lack of recruitment
- | ceralifimod (ONO 4641) / Ono Pharma
Trial termination, Trial primary completion date: DreaMS: Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jul 17, 2015
P2, N=343, Terminated, Sponsor: EMD Serono
Active, not recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Dec 2014; Merck has decided to not pursue phase 3 development of ceralifimod (ONO-4641). The decision was not related to any safety and efficacy findings
- New trial: A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Jul 8, 2015
P0, N=5, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- mocravimod (KRP-203) / Priothera
Trial primary completion date: A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies (clinicaltrials.gov) - Jul 2, 2015
P1, N=10, Recruiting, Sponsor: Novartis Pharmaceuticals
The decision was not related to any safety and efficacy findings Trial primary completion date: Jun 2016 --> Oct 2016
- ||| Tysabri (natalizumab) / Biogen, Royalty
Enrollment change: ESCALATE: Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies (clinicaltrials.gov) - Jun 29, 2015
P4, N=130, Recruiting, Sponsor: Biogen
Trial primary completion date: Jun 2016 --> Oct 2016 N=200 --> 130
- | Ponvory (ponesimod) / Juvise Pharma, Vanda
New P2 trial: Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD (clinicaltrials.gov) - Jun 24, 2015
P2, N=30, Not yet recruiting, Sponsor: Actelion
- | cenerimod (ACT-334441) / Idorsia
New P1 trial: Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 (clinicaltrials.gov) - Jun 24, 2015
P1, N=32, Recruiting, Sponsor: Actelion
- ||||| cenerimod (ACT-334441) / Idorsia
New P1/2 trial: Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - Jun 16, 2015
P1/2, N=64, Recruiting, Sponsor: Actelion
- || Trial primary completion date: MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (clinicaltrials.gov) - Jun 11, 2015
P4, N=2550, Recruiting, Sponsor: Novartis Pharmaceuticals
N=200 --> 130 Trial primary completion date: Jun 2020 --> Jun 2023
- || Zeposia (ozanimod) / BMS
Trial primary completion date: RADIANCE: Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients (clinicaltrials.gov) - Jun 11, 2015
P2, N=210, Active, not recruiting, Sponsor: Receptos, Inc.
Trial primary completion date: Jun 2020 --> Jun 2023 Trial primary completion date: Jun 2014 --> Apr 2016
- |||||| Zeposia (ozanimod) / BMS
Enrollment open: True North: Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Jun 5, 2015
P3, N=900, Recruiting, Sponsor: Receptos, Inc.
Trial primary completion date: Jun 2014 --> Apr 2016 Not yet recruiting --> Recruiting
- | Mayzent (siponimod) / Novartis
Trial completion, Enrollment change, Trial primary completion date: A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (clinicaltrials.gov) - Jun 4, 2015
P1, N=16, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed | N=48 --> 16 | Trial primary completion date: Jul 2015 --> Nov 2014
- |||||| Ponvory (ponesimod) / Juvise Pharma, Vanda
Enrollment open, Head-to-Head: OPTIMUM: Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis (clinicaltrials.gov) - May 24, 2015
P3, N=1100, Recruiting, Sponsor: Actelion
Recruiting --> Completed | N=48 --> 16 | Trial primary completion date: Jul 2015 --> Nov 2014 Not yet recruiting --> Recruiting
- | Ponvory (ponesimod) / Juvise Pharma, Vanda
Trial completion, Trial initiation date: Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects (clinicaltrials.gov) - May 21, 2015
P1, N=17, Completed, Sponsor: Actelion
Not yet recruiting --> Recruiting Recruiting --> Completed | Initiation date: Mar 2014 --> Aug 2014
- ||||| Velsipity (etrasimod) / Pfizer
New P2 trial: OASIS: Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis (clinicaltrials.gov) - May 19, 2015
P2, N=240, Not yet recruiting, Sponsor: Arena Pharmaceuticals
- |||||||||| Zeposia (ozanimod) / BMS
New P3 trial: True North: Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - May 6, 2015
P3, N=900, Not yet recruiting, Sponsor: Receptos, Inc.
- Trial termination: Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON) (clinicaltrials.gov) - May 4, 2015
P2, N=2, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Initiation date: Mar 2014 --> Aug 2014 Completed --> Terminated; Discontinuation of this study was based on Novartis decision to discontinue development of fingolimod for the treatment of ADON
- Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: BEST-MS: Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis (clinicaltrials.gov) - Apr 28, 2015
P4, N=600, Recruiting, Sponsor: University Hospital, Toulouse
Completed --> Terminated; Discontinuation of this study was based on Novartis decision to discontinue development of fingolimod for the treatment of ADON Trial primary completion date: Nov 2014 --> Oct 2015
- mocravimod (KRP-203) / Priothera
Trial primary completion date: A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies (clinicaltrials.gov) - Apr 25, 2015
P1, N=10, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2014 --> Oct 2015 Trial primary completion date: Jan 2016 --> Jun 2016
- |||| Trial primary completion date: OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - Apr 25, 2015
P3, N=700, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Apr 2017 --> May 2015
- |||| Trial primary completion date: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (clinicaltrials.gov) - Apr 25, 2015
P3, N=156, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2017 --> May 2015 Trial primary completion date: Feb 2016 --> Feb 2017
- |||||||||| Ponvory (ponesimod) / Juvise Pharma, Vanda
New P3 trial, Head-to-Head: OPTIMUM: Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis (clinicaltrials.gov) - Apr 25, 2015
P3, N=1100, Not yet recruiting, Sponsor: Actelion
- |||| Zeposia (ozanimod) / BMS
Trial primary completion date: Radiance: Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (clinicaltrials.gov) - Apr 18, 2015
P3, N=1200, Active, not recruiting, Sponsor: Receptos, Inc.
Trial primary completion date: Feb 2016 --> Feb 2017 Trial primary completion date: Nov 2017 --> Apr 2017
- | fingolimod / Generic mfg.
Enrollment open, Enrollment change: Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks (clinicaltrials.gov) - Apr 17, 2015
P4, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2017 --> Apr 2017 Not yet recruiting --> Recruiting | N=200 --> 40
- ||||||| Trial completion, Trial primary completion date: INFORMS: This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. (clinicaltrials.gov) - Apr 14, 2015
P3, N=969, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | N=200 --> 40 Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2014
- Enrollment closed, Trial primary completion date: Gilenya in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Apr 13, 2015
P2a, N=30, Active, not recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Sep 2014
- ||| fingolimod / Generic mfg.
Biomarker, New trial, IO biomarker: Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720) (clinicaltrials.gov) - Apr 3, 2015
P=N/A, N=216, Recruiting, Sponsor: McGill University
- |||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment open: Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease (clinicaltrials.gov) - Apr 3, 2015
P2, N=80, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- | iSONEP (sonepcizumab) / Pfizer, Apollo Endosurgery
Enrollment closed, Trial primary completion date: A Phase 2 Study of ASONEP (clinicaltrials.gov) - Mar 27, 2015
P2, N=39, Active, not recruiting, Sponsor: Lpath, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2015